US Patent Reference To Arthritis -- Plain Methyl Sulfonyl Methane -- Expired

Karl Note: These patents establish that MSM is effective in the reduction of pain. Each such use described here is what is called "plain MSM," and is NOT "Herbal MSM." MSM is manufactured from the raw material called DMSO. Click here for more information about DMSO. This claim for relief of arthritic pain has expired so that now such a claim is open for anyone to make about MSM.

Patent No.	Text From Patent Document
4,296,104 Oct. 20, 1981	The use of DMSO to reduce the mortality rate of fish treated by hyperosmotic delivery is also disclosed.
4,296,130 Oct. 20, 1981	In U.S. Pat. No. 4,296,130, I teach that methylsulfonylmethane is so inert and non-toxic that aqueous solutions thereof can be used as a blood diluent. In healthy humans or other animals having adequately high methylsulfonylmethane blood levels, methylsulfonylmethane is in fact "inert" in the sense the term is used in that patent. However, in acutely ill patients, dramatic beneficial benefits are often obtained by the intravenous administration of large doses of methylsulfonylmethane. For example, rheumatoid arthritic patients suffering from a flair-up of the disease which produces intense pain or crippling swelling of the joints or both achieve prompt relief, even those patients who obtain only minimal or delayed benefits from oral ingestion of methylsulfonylmethane. This is one of the patents which claims that MSM relieves the pain of arthritis. This claim was made in 1981, more than 20 years ago. Here is the claim that MSM can be effective in achieving "prompt relief" "for rheumatoid arthritic patients."
4,296,130	C. MSM Administered Orally Example 16 To determine whether living animal subject would react adversely to orally administered compositions of MSM, a 40 weight percent solution of MSM in distilled water was prepared. This solution was administered orally to laboratory rats at such a rate that each rat received 20 grams of MSM per kilogram of body weight per day. After six weeks of administration, none of the animals had died or displayed unusual symptoms or behavior. This patent has expired and covers a very large amount of uses and claims.
4,296,130	Example 19 To determine the safety of intravenous administrations of MSM compositions for blood dilution and/or systemic treatment of collagen related diseases, MSM was dissolved in a standard 5 percent dextrose solution so that the resulting liquid composition contained 20 weight pe-cent MSM. The composition was delivered intravenously to a dog weighing 9.5 kilograms at such a rate that the subject received 2 grams of MSM per kilogram of body weight per day. The subject did not react adversely to the intravenous administrations and did not require physical restraint. After several weeks of this treatment there was no evidence of physical discomfort or injury to the subject. "Collagen related diseases" include arthritis. Reference One. Reference Two. Reference Three, Reference Four, Reference Five, Thus a patent issued in 1981 to treat "collagen related diseases" includes the treatment of arthritis -- a patent that has expired and covers a very large amount of uses and claims.
*4,863,748* Sept. 5, 1989	Apparently, when a patient is in an acute stage of intense pain-producing disease, such as rheumatoid arthritis, osteoporosis, degenerative disc syndrome, an autoimmune disease or metathesized carcinoma, which produces intense pain, the relief from pain from oral ingestion of methylsulfonylmethane is sometimes too subtle or takes too long for the patient to obtain reasonably prompt subjective benefits therefrom. In contradistinction, intravenous administration of methylsulfonylmethane gives prompt, i.e., within hours and often within minutes, relief from pain and often dramatic benefits, e.g., a significant reduction in the crippling effects of rheumatoid arthritis.
*4,863,748*	In another method-of-use aspect, this invention relates to a method of inhibiting nocturnal and arthritic activity-induced muscle cramps in a person having a propensity for such muscle cramps, which comprises orally ingesting an amount of methylsulfonylmethane effective to inhibit the muscle cramps.
*4,863,748*	The following are pharmacological uses for methylsulfonylmethane in addition to its use in foodstuffs as described hereinabove: 4. Reducing or eliminating hypersensitivity problems associated with oral medications, such as non-steroidal antiarthritic agents. This effect may be the result of the interaction of the methylsulfonylmethane with plasma prostaglandin F2.
*4,863,748*	8. Improving the chemical profile of arthritic patients, e.g., providing relief from pain and stiffness, reduced swelling and inflammation, coupled with a return of blood chemistry towards normalcy, for example, a RH titer drop from 600+to 300 or lower.
*4,863,748*	Intravenous Administration In U.S. Pat. No. 4,296,130, I teach that methylsulfonylmethane is so inert and non-toxic that aqueous solutions thereof can be used as a blood diluent. In healthy humans or other animals having adequately high methylsulfonylmethane blood levels, methylsulfonylmethane is in fact "inert" in the sense the term is used in that patent. However, in acutely ill patiets, dramatic beneficial benefits are often obtained by the intravenous administration of large doses of methylsulfonylmethane. For example, rheumatoid arthritic patients suffering from a flair-up of the disease which produces intense pain or crippling swelling of the joints or both achieve prompt relief, even those patients who obtain only minimal or delayed benefits from oral ingestion of methylsulfonylmethane.
*4,863,748*	Siegel, (1985, Private Communication) has evaluated methylsulfonylmethane in mice with a genetic predisposition to a form of cancer and rheumatoid arthritis. The sulfone was administered orally. There was a significant delay in the development of lymphomas as well as decreased tumor incidence, compared with control. In addition and only grossly examined, treated animals demonstrated a marked reduction in joint involvement. An increased titer of primary IgM and secondary IgG was measured.
*4,863,748*	In another method-of-use aspect, this invention relates to a method of ameliorating the pain and discomfort associated with arthritis in an animal which comprises administering to an animal manifesting overt symptoms of the disease an amount of methylsulfonylmethane effective to ameliorate the pain.
*4,863,748*	One subject (M. P., F 81), presented chronic arthritis with painful involvement of the lower trunk. Over the years she had evaluated most new antiarthritic, analgesic drugs with disappointing results. She included methylsulfonylmethane (1/2 tsp. daily) in her diet and found almost total pain relief by the end of the second week. After ingesting methylsulfonylmethane daily at 1/4-1/2 tsp. for about 16 months, the subject is enjoying a substantially pain-free life.
5,071,878	J. J. Kocsis et al., Annals N.Y. Acad. Sci. 243, 104-109 (1975), cite literature which report that methylsulfonylmethane, a known metabolite of dimethylsulfoxide, persists for as long as three weeks after percutaneous application in man and one week after i.v. administration. The authors report that methylsulfonylmethane, like DMSO, enhances urinary taurine secretion produced by aromatic hydrocarbons in man, antagonizes the lethal effects of anticholinesterases such as paraoxon, tetraethyl pyrophosphate and octamethyl pyurophosphoramide; lowers the body temperature of rats exposed to 5.degree. C. temperature; and reduces motor activity (when administered i.p.). Kulshestha et al., C.A. 83; 22910n (1975), report that methylsulfonylmethane occurs naturally in a variety of fruits, vegetables and vegetable products, grains in at least trace amounts (3.3 ppm). T. W. Pearson et al., C.A. 95:113654W (1981). It is present in small amounts in normal urine. Williams et al., Archs. Biochem. Biophys. 1966, 113, 251-2. The following Chemical Abstracts refer to the biological aspects of methylsulfonylmethane as a DMSO metabolite, in cattle, 83:183a; Escherichia coli inhibition by, 83:72577e; nervous system depression by, 84:173608a; Salmonella typhimurium inhibition by, 82:71; of urine, 75:86025v; heart response to, 74:2429y; lung constrictivity activity of, 62:9634f; in tissue culture protection against X-rays, 58:9391e; toxicity of, ETOH and, 64:7229h; in urine after administration of, 65:17537g; in urine of humans, 64:10170g; and in urine as methylsulfonylmethane in mice with a genetic predisposition to a form of cancer and rheumatoid arthritis. The sulfone was administered orally. There was a significant delay in the development of lymphomas as well as decreased tumor incidence, compared with control. In addition and only grossly examined, treated animals demonstrated a marked reduction in joint involvement. An increased titer of primary IgM and secondary IgG was measured.
5,071,878	Apparently, when a patient is in an acute stage of intense pain-producing disease, such as rheumatoid arthritis, osteoporosis, degenerative disc syndrome, an autoimmune disease or metathesized carcinoma, which produces intense pain, the relief from pain from oral ingestion of methylsulfonylmethane is sometimes too subtle or takes too long for the patient to obtain reasonably prompt subjective benefits therefrom. In contradistinction, intravenous administration of methylsulfonylmethane gives prompt, i.e., within hours and often within minutes, relief from pain and often dramatic benefits, e.g., a significant reduction in the crippling effects of rheumatoid arthritis.
5,071,878	One subject (M.P., F 81), presented chronic arthritis with painful involvement of the lower trunk. Over the years she had evaluated most new antiarthritic, analgesic drugs with disappointing results. She included methylsulfonylmethane (1/2 tsp. daily) in her diet and found almost total pain relief by the end of the second week. After ingesting methylsulfonylmethane daily at 1/4-178 tsp. for about 16 months, the subject is enjoying a substantially pain-free life.
5,071,878	EXAMPLE 30 Canine Arthritis and Other Sources of Pain Methylsulfonylmethane was evaluated as an additive to the diet of older dogs of various breeds, all suffering from some form of arthritis and in some cases demonstrating other disorders. In each case the methylsulfonylmethane was admixed with the animal's food just prior to feeding.
5,071,878	(c) Dog C, a spayed, 14-year old German Shepherd, demonstrated severe arthritis of the back and legs. It was mobile but walked with obvious difficulty and discomfort. The animals was refractory to both cortisone and phenylbutazone. Methylsulfonylmethane was provided in the diet at a level of 0.5 grams b.i.d. There was gradual improvement in mobility over the first month. During the third month following methylsulfonylmethane supplementation of the diet, the dog demonstrated neither musculoskelatal restriction nor discomfort.
5,071,878	EXAMPLE 34 Intravenous Administration For patients suffering from a serious chronic disease, e.g., an acute stage of rheumatoid arthritis or other acute inflammatory conditions or a patient in extreme pain, administer 1 gm/kg of methylsulfonylmethane i.v. as a 14 % by wt. solution in sterile 5% dextrose solution, at the rate of 1 gm/kg/hr. Within 2-4 hours, significant subjective relief from the symptoms of the disease or condition is experienced by the patient, with the relief lasting for from 7 to 21 days.
5,071,878	4. Reducing or eliminating hypersensitivity problems associated with oral medications, such as non-steroidal antiarthritic agents. This effect may be the result of the interaction of the methylsulfonylmethane with plasma prostaglandin F2.
5,071,878	8. Improving the chemical profile of arthritic patients, e.g., providing relief from pain and stiffness, reduced swelling and inflammation, coupled with a return of blood chemistry towards normalcy, for example, a RH titer drop from 600+ to 300 or lower.
4,914,135	Siegel, (1985, Private Communication) has evaluated methylsulfonylmethane in mice with a genetic predisposition to a form of cancer and rheumatoid arthritis. The sulfone was administered orally. There was a significant delay in the development of lymphomas as well as decreased tumor incidence, compared with control. In addition and only grossly examined, treated animals demonstrated a marked reduction in joint involvement. An increased titer of primary IgM and secondary IgG was measured.
4,914,135	Apparently, when a patient is in an acute stage of intense pain-producing disease, such as rheumatoid arthritis, osteoporosis, degenerative disc syndrome, an autoimmune disease or metathesized carcinoma, which produces intense pain, the relief from pain from oral ingestion of methylsulfonylmethane is sometimes too subtle or takes too long for the patient to obtain reasonably prompt subjective benefits therefrom. In contradistinction, intravenous administration of methylsulfonylmethane gives prompt, i.e., within hours and often within minutes, relief from pain and often dramatic benefits, e.g., a significant reduction in the crippling effects of rheumatoid arthritis.
4,914,135	One subject (M.P., F 81), presented chronic arthritis with painful involvement of the lower trunk. Over the years she had evaluated most new antiarthritic, analgesic drugs with disappointing results. She included methylsulfonylmethane (1/2 tsp. daily) in her diet and found almost total pain relief by the end of the second week. After ingesting methylsulfonylmethane daily at 1/4-1/2 tsp. for about 16 months, the subject is enjoying a substantially pain-free life.
4,914,135	Canine Arthritis and Other Sources of Pain Methylsulfonylmethane was evaluated as an additive to the diet of older dogs of various breeds, all suffering from some form of arthritis and in some cases demonstrating other disorders. In each case the methylsulfonylmethane was admixed with the animal's food just prior to feeding.
4,914,135	(c) Dog C, a spayed, 14-year old German Shepherd, demonstrated severe arthritis of the back and legs. It was mobile but walked with obvious difficulty and discomfort. The animals was refractory to both cortisone and phenylbutazone. Methylsulfonylmethane was provided in the diet at a level of 0.5 grams b.i.d. There was gradual improvement in mobility over the first month. During the third month following methylsulfonylmethane supplementation of the diet, the dog demonstrated neither musculoskelatal restriction nor discomfort.
4,914,135	Intravenous Administration For patients suffering from a serious chronic disease, e.g., an acute stage of rheumatoid arthritis or other acute inflammatory conditions or a patient in extreme pain, administer 1 gm/kg of methylsulfonylmethane i.v. as a 14% by wt. solution in sterile 5% dextrose solution, at the rate of 1 gm/kg/hr. Within 2-4 hours, significant subjective relief from the sypmtoms of the disease or condition is experienced by the patient, with the relief lasting for from 7 to 21 days. Such massive i.v. administration can be repeated as frequently as every 24 hours. Rates of dimethylsulfone administration as high as 2 gm/kg/hr are possible but may produce transient light-headedness in the patient.
4,973,605 November 27, 1990	*Claims* 1. A method for inhibiting nocturnal and arthritic activity-induced muscle cramps in a person having a propensity for such muscle cramps, which comprises orally ingesting an amount of methylsulfonylmethane effective to inhibit the muscle cramps.
4,973,605	*Claims* 2. A method according to claim 1, wherein the person is a geriatric experiencing reoccurring nocturnal muscle cramps.
4,973,605	*Claims* 3. A method according to claim 1, wherein at least about 10 mg of methylsulfonylmethane is ingested daily for a succession of days.
4,973,605	*Claims* 4. A method according to claim 3 of ameliorating the pain and discomfort associated with arthritis in an animal which comprises administering to an animal manifesting overt symptoms of the disease an amount of methylsulfonylmethane effective to ameliorate the pain.
4,973,605	*Claims* 5. A method according to claim 4, wherein the animal is a human being.
4,973,605	*Claims* 6. A method according to claim 5, wherein the arthritis is rheumatoid arthritis.
4,973,605	*Claims* 7. A method according to claim 6, wherein the methylsulfonylmethane is administered orally on successive days.
4,973,605	*Claims* 10. A method according to claim 3 of alleviating intractible pain, which comprises administering intravenously to a patient suffering from a disease producing such pain an amount of methylsulfonylmethane effective to alleviate the pain.
4,973,605	*Claims* 11. A method according to claim 10, wherein the methylsulfonylmethane is administered as an aqueous solution over a period of at least 1/2 hour.
4,973,605	*Claims* 12. A method according to claim 10, wherein at least about 1 mg/kg of body weight of the methylsulfonylmethane is administered.
4,973,605	*Claims* 13. A method according to claim 10, wherein the disease is rheumatoid arthritis.
4,973,605	*Claims* 14. A method of ameliorating the pain and discomfort associated with arthritis, or with nocturnal or arthritic activity-induced muscle cramps, with gastric hyperactivity or with intractable pain, which comprises administering to the animal or individual suffering from such pain an amount of methylsulfonylmethane effective to ameliorate the pain.
4,973,605	Siegel, (1985, Private Communication) has evaluated methylsulfonylmethane in mice with a genetic predisposition to a form of cancer and rheumatoid arthritis. The sulfone was administered orally. There was a significant delay in the development of lymphomas as well as decreased tumor incidence, compared with control. In addition and only grossly examined, treated animals demonstrated a marked reduction in joint involvement. An increased titer of primary IgM and secondary IgG was measured.
4,973,605	SUMMARY OF THE INVENTION In a method-of-use aspect, this invention relates to a method of ameliorating the pain and discomfort associated with arthritis in an animal which comprises administering to an animal manifesting overt symptoms of the disease an amount of methylsulfonylmethane effective to ameliorate the pain.
4,973,605	Apparently, when a patient is in an acute stage of intense pain-producing disease, such as rheumatoid arthritis, osteoporosis, degenerative disc syndrome, an autoimmune disease or metathesized carcinoma, which produces intense pain, the relief from pain from oral ingestion of methylsulfonylmethane is sometimes too subtle or takes too long for the patient to obtain reasonably prompt subjective benefits therefrom. In contradistinction, intravenous administration of methylsulfonylmethane gives prompt, i.e., within hours and often within minutes, relief from pain and often dramatic benefits, e.g., a significant reduction in the crippling effects of rheumatoid arthritis.
4,973,605	One subject (M.P., F 81), presented chronic arthritis with painful involvement of the lower trunk. Over the years she had evaluated most new antiarthritic, analgesic drugs with disappointing results. She included methylsulfonylmethane (1/2 tsp. daily) in her diet and found almost total pain relief by the end of the second week. After ingesting methylsulfonylmethane daily at 1/4-1/2 tsp. for about 16 months, the subject is enjoying a substantially pain-free life.
4,973,605	Example 30 - Canine Arthritis and Other Sources of Pain Methylsulfonylmethane was evaluated as an additive to the diet of older dogs of various breeds, all suffering from some form of arthritis and in some cases demonstrating other disorders. In each case the methylsulfonylmethane was admixed with the animal's food just prior to feeding.
4,973,605	(c) Dog C, a spayed, 14-year old German Shepherd, demonstrated severe arthritis of the back and legs. It was mobile but walked with obvious difficulty and discomfort. The animals was refractory to both cortisone and phenylbutazone. Methylsulfonylmethane was provided in the diet at a level of 0.5 grams b.i.d. There was gradual improvement in mobility over the first month. During the third month following methylsulfonylmethane supplementation of the diet, the dog demonstrated neither musculoskelatal restriction nor discomfort.
4,973,605	Example 34 - Intravenous Administration For patients suffering from a serious chronic disease, e.g., an acute stage of rheumatoid arthritis or other acute inflammatory conditions or a patient in extreme pain, administer 1 gm/kg of methylsulfonylmethane i.v. as a 14% by wt. solution in sterile 5% dextrose solution, at the rate of 1 gm/kg/hr. Within 2-4 hours, significant subjective relief from the symptoms of the disease or condition is experienced by the patient, with the relief lasting for from 7 to 21 days.
4,973,605	In another method-of-use aspect, this invention relates to a method of inhibiting nocturnal and arthritic and activity-induced muscle cramps in a person having a propensity for such muscle cramps, which comprises orally administering thereto an amount of methylsulfonylmethane effective to inhibit the muscle cramps.

Table Of Contents	Relief Of Arthritis Pain	Relief Of The Pain Of Fibromyalgia
Write To Karl Loren -- He Pledges To Answer EVERY Personal Message, Personally. Click here or on his name in the box below.

I promise to answer your message -- click here to send me a personal message

Dear Karl,

You can reach Karl Loren at www.PainStudy.com by mail at 1831 N. Bel Aire Drive, Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to karl@painstudy.com

Copyright © May 20, 2008 6:26 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.